Cambridge, Mass., USA - Inhibikase Therapeutics, a pharma company, announced the election of Richard Fante and the election of Patrick Vink to its board.
Article continues below
Mr. Fante serves as President of RF Consulting LLC since April 11, 2013, a private pharmaceutical consulting business that advises clients on commercial assessments and go-to-market strategies. Prior to founding RF Consulting, he spent over nineteen years at AstraZeneca Pharmaceuticals in the United States.
Mr. Fante served most recently as President U.S.A. and CEO North America and Regional Vice President for the Americas.
Prior to assuming his role as President AstraZeneca U.S.A., he served as the head of Brand Strategy and Portfolio Operations at AstraZeneca.
Before joining AstraZeneca in January 1995, Mr. Fante worked at Lederle Laboratories where he started his career as a sales representative.
He served as Board Chairman of the National Pharmaceutical Council (2012) and was a member of the Institute of Medicine of the National Academies of Science Roundtable on Value and Science.
Mr. Fante holds a BA in Biology fromPrinceton University and an MBA from the University of North Carolina Chapel Hill.
Mr. Vink is currently an advisor to the pharmaceutical industry and joins the Inhibikase Board following 3+ years at Cubist Pharmaceuticals, where he served as Executive Vice-President and Chief Operating Officer, overseeing all worldwide commercial and technical operations as well as global alliance management.
Mr. Vink joined Cubist in 2012 as Senior Vice-president and Head of all International Business Operations. In this role he was responsible for the all business activities in International markets outside USA.
Prior to joining Cubist, he served as Senior Vice President, Global Head of Hospital Business and Global Head of Biologics for Mylan Inc. In this role, he coordinated all hospital business of the company.
Mr. Vink joined Mylan in 2008 and established the company's operations in Switzerland, which were the basis of a number of global functions.
Before joining Mylan, he held several leadership positions across the industry, including Head of Global Business Franchise Biopharmaceuticals for Novartis Sandoz; Vice-President International Sales for Biogen; and Head of Worldwide Marketing, Cardiovascular and Thrombosis for Sanofi-Synthelabo.
Mr. Vink has served as a member of the Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) between 2013 and 2015.
He graduated as a medical doctor from the University of Leiden, Netherlands in 1988 and obtained his MBA in 1992 at the University of Rochester.
Anthony Zook has stepped down from the Board due to his new role as CEO of Innocoll AG.
Mr. Zook was apppointed to Board on November 21, 2013. A 30-year veteran of the biopharmaceutical industry, he joined AstraZeneca (AZ) as Vice-President of Sales for the U.S. Business in 1999.
By 2001, he rose to Senior Vice President of AZ's US Commercial Operations and became Executive Vice President, CEO and President of AZ North America in 2006.
In 2008, Mr. Zook assumed responsibility for Global Marketing, and was also appointed President of AZ's biologic division, MedImmune.
In 2010, he transitioned to a global operations role when he was promoted to EVP of Global Commercial Operations for AZ, retiring from that position and the Company in 2013.
Following his 14-year career at AZ, Mr. Zook became CEO of Vivus. He then became a member of the Board of Directors of AltheRx Pharmaceuticals.
Mr. Zook received his Associates Degree in Chemical Engineering from Penn State and his B.S. in Biology with a minor in Chemistry from Frostburg University. ■